Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

• Status: Completed
• Trial end date: 2021-06-22
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to evaluate the rate of subjects with HBV DNA less than 20 IU/mL after taking TenofoBell® tablet for 48 weeks

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical

Criteria

1. Inclusion Criteria:

1. Patients who show positive HBsAg

2. Patients who show positive or negative HBeAg

2. Exclusion Criteria:

1. Patients who have hepatitis C(HCV), hepatitis D(HDV) or human immunodeficiency virus(HIV)

2. Patients with a history of allergic reaction to Tenofovir

3. Patients who are unable to participate in clinical trials based on investigator's decision.